UNSPSC 51204213: Hog cholera vaccine

Hog cholera virus grown in PK 15 cells has been concentrated, inactivated with glyceraldehyde, and then mixed with an oil adjuvant; and inoculation of 5 ml of this vaccine has induced a solid and long-lasting immunity.

UNSPSC 51204213 Hog cholera vaccine is a Commodity code that in recent state and local activity covers immunological products procured by health departments, though the sole documented recent opportunity does not involve hog cholera specifically. The Mississippi State Department of Health posted a sole source procurement notice on July 13, 2026 for Yellow Fever Vaccine from Sanofi Pasteur, Inc., with objections due August 3, 2026, indicating that state health agencies use this code to acquire vaccines across multiple disease targets. The scope of work under this code encompasses acquisition of finished vaccine products from established pharmaceutical manufacturers, with procurement triggered by public health preparedness and disease surveillance needs. State health departments appear to be the primary issuing bodies soliciting under this code, though the recent-opportunities block contains only a single record and does not support characterization of issuing-body mix across multiple jurisdictions or repeat buyers.

The sole recent opportunity is concentrated in a single state jurisdiction — Mississippi — and does not provide sufficient geographic spread to characterize regional or multi-state activity patterns. The Mississippi State Department of Health's notice is structured as a sole source proposal rather than open competitive bidding, meaning objections to sole source designation (submitted to Cynthia Brasher at Cynthia.brasher@msdh.ms.gov) trigger potential conversion to advertised competitive process; the notice does not disclose quantity, contract term, or estimated value. The mismatch between the code's nominal focus (hog cholera) and the recent Yellow Fever Vaccine solicitation suggests either misclassification in the state procurement system or broad application of the vaccine Commodity code across multiple immunological products. The available data does not support robust characterization of current market activity or competitive opportunity volume under this code.